Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
crovalimab
- Development stage
- Approved
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Crovalimab is a humanized monoclonal antibody that acts as a complement C5 inhibitor. It is used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults and adolescents. Crovalimab binds with high affinity to the complement protein C5, blocking its cleavage into C5a and C5b, thereby preventing the formation of the membrane attack complex (MAC) and inhibiting terminal complement-mediated intravascular hemolysis. This mechanism reduces red blood cell destruction in PNH patients. Crovalimab employs an anti-C5 sequential monoclonal antibody recycling technology, allowing repeated binding to its target for sustained inhibition. The drug was developed by Chugai Pharmaceutical in collaboration with Roche and has been approved in China, Japan, and the USA for PNH[2][6][7].
- Brand names
- Piasky
- Other names
- crovalimab-akkz
02
Targets
C5
Beyond the preview
Go deeper on crovalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on crovalimab.